Clinical research
Vertos Medical is committed to building the science behind its mild* procedure. Working with a scientific advisory board composed of clinical experts in pain medicine and neurosurgery, the company has developed a comprehensive clinical program to validate the safety and efficacy of the mild devices and procedure. This program includes several postmarket clinical studies at leading pain centers across the country.
mild Postmarket Clinical Studies
Completed
- mild Acute Safety Study: 90-patient, multi-center, retrospective study, with results published in Pain Physician Journal
See press release on study findings
See Pain Physician Journal article
Ongoing
- MiDAS I (mild® Decompression Alternative to open Surgery): 75-patient, open-label, single-arm, prospective, multi-center, IRB-approved study; enrollment completed
See press release on six-week study findings
See press release on twelve-week study findings
See Pain Physician article
- MiDAS II: 50-patient, open label, single-arm, multi-center, prospective IRB-approved study; now enrolling
- ESI-I Trial: 40-patient, single-site, randomized, double-blind, prospective, IRB-approved study comparing mild and epidural steroid injections; now enrolling
- ESI-II Trial: 150-patient, multi-site, randomized, double-blind, prospective, IRB-approved study comparing mild and epidural steroid injections; future enrollment
- Prospective Patient Series: 50-patient, single-site, open label, single-arm, prospective, IRB-approved study; now enrolling
- High Risk Trial: 14-patient, single-site, open label, single-arm, prospective, IRB-approved study on high-risk patients; enrollment completed
Fully detailed study methodologies are available upon request.
*Cleared by the U.S. Food and Drug Administration for lumbar decompression, Vertos mild is designed to treat lumbar spinal stenosis (LSS).
